This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Aging/ Geriatrics  • Neurology  • Alzheimer Disease  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2008;300(11):1287-1289.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—Although efforts to develop treatments for Alzheimer disease have met limited success to date, some experts are heartened by new findings from studies of several experimental Alzheimer disease therapies. While the results, reported at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD), held here in July, were mixed and most of the particularly promising drugs will require additional study, researchers are optimistic that several agents may eventually change the landscape of Alzheimer disease treatment.

"We are making progress. It is very important that we have as many drugs as possible in the pipeline for Alzheimer's and that we explore every available avenue for treatment," said Ralph Nixon, MD, PhD, of the New York University School of Medicine in New York City and a member of the Alzheimer's Association's Medical and Scientific Advisory Council.

Experimental treatments for Alzheimer disease target amyloid plaques (above) and other . . . [Full Text of this Article]

NEGATIVE PHASE 3 STUDY



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?